Less than a tenth of patients who could benefit from weight-loss injections like Wegovy are able to get them, warns the World Health Organization as it issues its first recommendations on the medications.
Given in excess of 1,000,000,000 individuals worldwide currently classified as obese, it is advocating for more widespread and fairer access to this class of drugs.
According to estimates, more than two billion could be obese by 2030 unless action is taken.
"Our new guidelines affirms that excess weight is a lifelong illness that can be treated with holistic and ongoing support," remarked WHO director-general Tedros Adhanom Ghebreyesus.
Substantial prices, limited production capacity, and distribution challenges are significant obstacles to broad access to the injections that can assist patients in reducing significant body mass, says the body.
Skinny Jab Shortage
Despite the present most favorable scenario, the manufacturing of such drugs could only cover approximately 100 million people – fewer than 10% of eligible patients, as stated by the WHO.
The advice urges nations and manufacturers to increase access, via approaches including patent sharing.
A patent on a key compound – the main component of the drug Wegovy – is set to lapse in several countries in 2026.
The Way Weight-Loss Injections Operate
The injections replicate a biological compound to delay gastric emptying, reduce hunger and enhance the sense of being full so people reduce food intake.
Individuals commonly see weight reduction after several weeks of starting on the weekly injections.
Studies indicates users may see weight return after a year of discontinuing the drug, as their typical hunger return.
Being overweight or obese raises your risk for experiencing medical conditions, including diabetes, cardiovascular issues, brain attack, and specific malignancies.
Excess weight concerns individuals in all nations and was associated with millions of fatalities worldwide in 2024, as per the health agency.
